Having trouble accessing articles? Reset your cache.

Regeneron halting higher doses in fasinumab trials

In its 1Q18 earnings, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab (REGN475). Regeneron will

Read the full 270 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE